PITTSBURGH — Mylan Inc. has launched irbesartan tablets and irbesartan and hydrochlorothiazide tablets, indicated for treating high blood pressure.
The company said Friday that its irbesartan tablets come in strengths of 75 mg, 150 mg and 300 mg and are the generic version of Sanofi’s Avapro.
Mylan’s irbesartan and hydrochlorothiazide tablets, available in dosages of 150/12.5mg and 300/12.5 mg, are the generic version of Sanofi’s Avalide.
Irbesartan tablets are indicated for the treatment of hypertension and in patients with type 2 diabetic nephropathy, while irbesartan/hydrochlorothiazide tablets are for treating high blood pressure in patients not adequately controlled with a single drug, and as initial therapy in patients likely to need multiple drugs to achieve blood pressure control.
For the 12 months ended June 30, irbesartan tablets had U.S. sales of about $400.7 million, and irbesartan/hydrochlorothiazide tablets totaled sales of approximately $117.4 million, according to IMS Health data reported by Mylan.
